GSK enters drug discovery collaboration with AI-driven company
GSK has entered into a strategic drug discovery collaboration with an artificial intelligence-driven (AI) drug discovery company, Exscientia.
Under the agreement, Exscientia will apply its AI-enabled platform in combination with GSK’s expertise to discover novel and selective small molecules for ten diseases.
GSK will also pay Exscientia to undertake new discovery programmes.
According to a statement released on Sunday, July 2, Exscientia will also be eligible to get a milestone payment of £33 million ($43 million) if all objectives are achieved.
Andrew Hopkins, CEO of Exscientia, said: "The alliance provides further validation of our AI-driven platform and its potential to accelerate the discovery of novel, high-quality drug candidates."
John Baldoni, senior vice president at GSK, added: "We anticipate that their industry-leading approach will accelerate the discovery of new molecules against high-value GSK targets with speed and confidence, and without compromising quality."
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Today’s stories:
Concerns over Merck and Sigma-Aldrich merger
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk